Pharmaceutical service in statinsinduced Rhabdomyolysis by clinical pharmacists

doi:10.12092/j.issn.1009-2501.2018.06.018

Abstract

Abstract:

AIM: To explore the pharmaceutical services of clinical pharmacists in rhabdomyolysis caused by statins. METHODS: Clinical pharmacist participated in the assessment and treatment of three patients of rhabdomyolysis caused by statins, analyzed and summarized the pharmaceutical services of clinical pharmacists in it. RESULTS: Clinical pharmacists provided Pharmaceutical Care of rhabdomyolysis caused by statins, conducted the relevance evaluation of Adverse Drug Reactions, analyzed the risk factors of rhabdomyolysis caused by statins, and offered corresponding pharmaceutical services. CONCLUSION: Clinical pharmacists can provide pharmaceutical service on entry point of relevance evaluation of Adverse Drug Reactions, focusing on risk factors, giving Medical education in rhabdomyolysis patients induced by statins.

Key words: rhabdomyolysis, statins, clinical pharmacist, phamaceutical service

CLC Number:

R969.3

YUAN Yumei, WANG Ronghua, YANG Shuixin. Pharmaceutical service in statinsinduced Rhabdomyolysis by clinical pharmacists[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 704-708.

References

［1］Tonelli M, Lloyd A, Clement F, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis［J］. CMAJ, 2011, 183(16): E1189-1202.
［2］Joy TR, Hegele RA. Narrative review: statin-related myopathy［J］. Ann Intern Med, 2009, 150(12): 858-868.
［3］Khan FY. Rhabdomyolysis: a review of the literature［J］. Neth J Med, 2009, 67(9): 272-283.
［4］Torres PA, Helmstetter JA, Kaye AM, et al. Rhabdomyolysis: pathogenesis, diagnosis, and treatment［J］. Ochsner J, 2015, 15(1):58-69.
［5］Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipidlowering drugs［J］. JAMA, 2004, 292: 2585-2590.
［6］江岳鑫, 娄莹, 刘玉清, 等. 他汀类药物致160 例肌病相关不良反应的临床分析［J］. 中华高血压杂志, 2014, 42: (11): 905-909.
［7］黄惠明. 20082013年他汀类药物致横纹肌溶解症文献分析［J］. 中国药物应用与监测, 2014, 11(2): 107-110.
［8］Albayda J, ChristopherStine L. Identifying statinassociated autoimmue necrotizing myopathy ［J］. Cleve Clin J Med, 2014, 81:736-741.
［9］Vrablik M, Zlatohlavek L, Stulc T, et al. Statin-associated myopathy: from genetic predisposition to clinical management［J］. PhysiolRes, 2014, 63Suppl3: S327-334.
［10］Abramson JD, Rosenberg HG, Jewel N, et al. Should people at low risk of cardiovascular disease take a statin［J］? BMJ, 2013, 347: f6123.
［11］刘建平, 邢建民. 循证的药品不良反应评价方法［J］. 中国药物警戒, 2010, 7(1): 12-15.
［12］Ramkumar S , Raghunath A , Raghunath S . Statin Therapy: Review of Safety and Potential Side Effects［J］. Acta Cardiol Sin, 2016, 32 (6): 631-639.
［13］HuertaAlardn AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysisan overview for clinicians［J］. Crit Care, 2005, 9(2):158-169.
［14］Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with highdosage statin therapy in hyperlipidemic patientsthe PRIMO study［J］. Cardiovasc Drugs Ther, 2005, 19(6): 403-414.
［15］Frydrychowicz C, Pasieka B, Pierer M, et al. Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case report［J］. J Med Case Rep, 2017, 11(1):8-13.
［16］Duncan SJ, Howden CW. Proton Pump Inhibitors and Risk of Rhabdomyolysis［J］. Drug Saf, 2017, 40(1): 61-64.
［17］Li DQ, Kim R, McArthur E, et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4［J］. CMAJ, 2015, 187(3):174-180.
［18］Hirota T, Ieiri I. Drug-drug interactions that interfere with statin metabolism［J］. Expert Opin Drug Metab Toxicol, 2015, 10: 1-13.
［19］Blaier O, Lishner M, Elis A. Managing statin-induced muscle toxicity in a lipid clinic［J］. J Clin Pharm Ther, 2011, 36(3):336-341.
［20］Simons JE, Holbrook AM, Don-Wauchope AC. Successful reintroduction of statin therapy after statin-associated rhabdomyolysis［J］. J Clin Lipidol, 2015, 9(4):594-596.
［21］熊贤兵, 李刚, 罗文艳, 等. 1例辛伐他汀联用罗红霉素致横纹肌溶解患者的药学监护［J］. 中南药学, 2015, 13(6): 660-662.
［22］中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南（2016年修订版）［J］. 中国循环杂志, 2016, 31(10): 937-953.

[1]	ZHAO Lu, LI Fuyong, WEN Binhong, LI Daowei. Effects of stains on hyperlipidemia and pain relieve of patients with chronic migraine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 671-675.
[2]	ZHANG Zhaowei, LI Zuojun, HUANG Jian, LI Shuangqing, HE YiLin. Exploring the outbreak point for clinical pharmacists to provide pharmaceutical care in nephrology department [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 184-188.
[3]	YU Yahong, SONG Yu. Pharmacotherapy of patients with left ventricular assist devices [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 198-204.
[4]	WANG Fengling, MENG Xiangyun, CHEN Zhengxu, CAO Rongjuan, HE Zhengmin, YE Xi, WANG Cong, LI Qi. Analysis on genetic polymorphism of SLCO1B1 and ApoE in patients with cardiovascular diseases of Han nationality in Anhui area and its clinical significance for individualized use of statins [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 40-48.
[5]	ZHOU Haihui, ZHANG Haixia, GE Weihong. Analysis of the role of clinical pharmacist in the establishment of standardized cancer pain management ward [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1038-1042.
[6]	YANG Rui, LIU Hui, CHEN Zeheng, QI Tingting，ZHANG Zanling, QU Qiang. Clinical pharmacists use CYP2C19 genotyping test to guide individual medication therapy of Clopidogrel and to evaluate the efficacy of treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 938-943.
[7]	ZHU Xuting, HANG Yongfu. Clinical pharmacists' pharmaceutical care and practice in the department of nephrology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1174-1178.
[8]	LI Nan，HUANG Haitao，YONG Xiaolan. Pharmaceutical care for a patient misdiagnosed as Staphylococcus intermedius pulmonary infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1067-1071.
[9]	DANG Xiangji, ZHOU Lin, WANG Yixuan, ZENG Lu. Individualized antithrombotic therapy on one patient with chronic renal insufficiency [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 477-480.
[10]	YU Yang, HE Jiake, XIONG Aizhen, DING Nan. Role of clinical pharmacists in the anti-infective therapy after anterior cruciate ligament reconstructions: an individualized medicine perspective [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 194-197.
[11]	DENG Junli, ZHANG Rui, TANG Jie, WANG Guo, ZHU Yuanshan. Research progress on the anti-tumor effects of statins [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 92-99.
[12]	ZHANG Wen, WANG Lin, XU Wen-ke. Effects of examining prescriptions on rational application of antibiotics in diabetes patients combined with urinary tract infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(4): 420-424.
[13]	WANG Yu, HU Xiao-lei, TANG Min. Pharmaceutical care for clinical therapy in a patient with bacteremia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(4): 415-418.
[14]	YUE Hui-jie, TAO Ying-ying, SONG Xiao-jun. Case analysis of clinical pharmacist participating in the therapy of cryptogenic organizing pneumonia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1361-1364.
[15]	LIN Qi, DAI Wen-sen, GUO Li-jing. Approaches for clinical pharmacists to implement pharmaceutical care for bronchiectasis patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1238-1240.